List of Vaccines Companies in Germany - 17

ARTES Biotechnology is a globally working, well established and reliabletechnology provider for recombinant protein production. They develop microbial cell lines and processes for vaccines, biopharmaceuticals, biosimilars and enzymes and offer ready-to-transfer processes for a wide range of products.

BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and develop-ment time of next-generation biotherapeutics from approx. 3 years to 12 months. It will save valuable time in the fight against cancer and significantly reduce the cost of cancer therapeutics. In the long term, BioCopy will expand its efforts beyond cancer and develop biotherapeutics for immunological and neurological diseases. The company is managed by Dr Matthias Wiedenfels, a proven expert and industry insider in the pharmaceutical and biotechnology industry, not least through his time as CEO of STADA Arzneimittel AG.

BioNTech is a global next generation immunotherapy company aspiring to translate science into survival. Around 6.100 pioneers currently work with us, employing a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules.   Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. To learn more about us, please visit www.BioNTech.com. Our privacy statement can be found here:  https://www.biontech.com/int/en/home/data-privacy-statement.html Our imprint can be found: https://www.biontech.com/int/en/home/imprint.html

CORAT develops phage-display derived fully human antibodies into passive vaccines to treat and to protect against COVID-19

CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.

Over 700 doctors and scientists from 35 establishments collaborate at the German Center for Infection Research (DZIF), jointly developing new approaches to prevent, diagnose and treat infectious diseases. This synergistic alliance of universities, hospitals and research institutions has established a globally unique infrastructure—aiming to effectively translate research results from bench to bedside, and vice versa: applying insights from clinical practice to research.

IDT Biologika is your full-service CDMO for viral vaccines, cell & gene therapeutics and other biologics protecting humans worldwide! We are committed to your development and manufacturing needs from the early stages of process development to clinical trial materials and commercial manufacturing: • Process Development • Clinical & Commercial Scale Drug Substance (e.g. Viral Vaccines, Viral Vectors for Cell and Gene Therapeutics) • Aseptic Liquid Filling & Lyophilization (Biologics) • Labeling, Packaging & Storage • Quality Control and Analytical Services With the expertise and capacity to handle large-scale campaign production of human vaccines and biopharmaceuticals, IDT Biologika brings development, testing and regulatory excellence along with state-of-the-art manufacturing lines required to advance projects with the highest level of quality, efficiency and consistency of supply: • FDA, EMA, ANVISA standards European and North American Footprint IDT Biologika is headquartered in Germany (Dessau-Rosslau and Magdeburg in Saxony-Anhalt). Here we operate one of Europe's premier integrated biopharmaceutical facilities for end-to-end services: • Process Development • Clinical Phases I-III • Commercial Scale Drug Substance (e.g. Viral Vaccines, Viral Vectors for Cell and Gene Therapeutics) • Commercial Manufacturing • Aseptic Liquid Filling & Lyophilization (Biologics) • Labeling, Packaging & Storage • Quality Control and Analytical Services Our North American facility is in Rockville, Maryland. The site has a long history of contract manufacturing and state-of-the-art technologies used to develop and manufacture clinical trial materials for phases I–II: • Process Development • Clinical-Scale Drug Substance (Viral Vaccines, Viral Vectors for Cell & Gene Therapeutics) • Aseptic Liquid Filling & Lyophilization • Packaging & Storage • Analytical Service

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tubingen, Germany.

We are the Peptide Experts! JPT has a large peptide synthesis capacity, providing over 1 million peptides per year. We offer all possible peptide modifications such as macrocyclic peptides, phosphorylated peptides, labeled and tagged peptides, radioligands, isotope labeling and more. Made in Germany Global Support More than 20 Years of Expertise Ethical, Environmental & Health Standards Portfolio: Custom Peptides Our patented technologies in peptide libraries, pools, microarrays, and micro-scale synthesis set us apart as a leader in the field. From micro to large-scale synthesis, our state-of-the-art labs in Germany deliver peptides tailored to your needs. Modified Peptides We produce modified peptides such as long and stapled peptides, dyes, labeled and biotinylated peptides, PTMs, unique building blocks, conjugations, macrocyclic peptides and more. PepMix Peptide Pools Peptide pools for antigen-specific T-cell stimulation in immune monitoring, assay control, cell therapy development, T-cell expansion etc. In addition to custom PepMix peptide pools we have more than 500 PepMixes in stock, for example: Control Pools: CEFX, CEF, Actin, CMV pp65 … Viral Proteins of EBV, SARS-CoV-2, CMV, VZV, HPV … TAA: Prame, NY-ESO-1, MART-1, MAGE A … Clinical Peptides & Pools Our resulting Clinical Grade Peptides have been approved for a variety of clinical applications including immunotherapy and vaccine development, immune monitoring, and clinical proteomics. Please visit our website for more information! JPT Peptide Technologies GmbH Management: Aurélien Claeyssen, Jens Holstein, Dr. Sierk Poetting Volmerstr. 5 D- 12489 Berlin T: +49 30 6392 5500 peptide@jpt.com https://www.jpt.com/ Registration Court: Berlin / Amtsgericht Charlottenburg, HRB 92692 VAT identification number: DE 814044483 Imprint: https://www.jpt.com/support-contact/corporate/imprint/ Privacy Policy: https://www.jpt.com/support-contact/corporate/privacy-policy/

Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The Company uses its small molecule-based drug candidates to build a pipeline in several indications, in-house or via strategic partnerships, as single agent, or in combination with checkpoint inhibitors, other drugs or antigens. Its drug candidate KUP101 is the only TLR 4/7 agonist in development and consists of two small molecules, TLR4 agonist and TLR7 agonist, co-encapsulated. IND-enabling work is on-going for treatment of solid tumors and prophylaxis of infectious diseases. Kupando is a private company, seed financed by its CEO Johanna Holldack and based on technology invented by Dennis Carson’s Laboratory at the University of California San Diego. The Company’s management team brings a unique wealth of experience in business and drug development, gained in the US and Europe. Kupando is headquartered in Schoenefeld, Germany.

We are a German biotech company with a dis­­­­tinctive strategy to fight cancer. Our three academic cancer projects have demonstrated clinical proof of concept and are ready for final development by pharma.

Paul-Ehrlich-Institut is a healthcare regulatory agency that oversees pharmaceuticals, approves vaccines, conducts biomedical research, and protects public health.

PEPperPRINT is an innovative biotech company from Heidelberg, Germany, and the leading provider of high density peptide and protein microarrays for antibody characterization or the fingerprint analysis of antibody responses from biological samples. The product and service portfolio was recently complemented by T cell epitope mapping and monitoring, making PEPperPRINT a one-stop solution provider for the fingerprint analysis of immune responses e.g. for epitope mapping, antibody biomarker discovery or the analysis of adverse immune effects. PEPperPRINT’s peptide microarrays and screening services have been used by researchers around the world with over 200 peer-reviewed publications.

PlasmidFactory GmbH, based in Bielefeld, Germany, is the leading contract manufacturer of plasmid and minicircle DNA. The company offers the production of plasmids and minicircles in several quality grades: Research Grade and ccc Grade for research purposes and pre-clinical applications, High Quality (HQ) Grade as starting material for e.g. GMP production of RNA and viral vectors and GMP Grade for clinical applications. PlasmidFactory has its own separate, dedicated HQ production area with new laboratories to produce highly purified plasmid DNA. To avoid cross-contamination, only one plasmid per time is produced there. Besides production of individual plasmids and minicircles, In Stock products that are deliverable immediately off the shelf, are also provided: e.g. reporter genes (gfp, lacZ, luc), AAV Helper & Packaging vectors (pDG/pDP family, several serotypes) or pEPI plasmids (containing S/MAR elements). PlasmidFactory is working on several research topics – some in close co-operation with industrial and academic partners.

ProBioGen is a renowned contract development and manufacturing organization (CDMO) and technology provider. We perform cell line engineering, process development, and GMP manufacturing of biopharmaceuticals for clients in biotech and pharma. We offer proprietary innovative technologies for optimized biopharmaceutical manufacturing and analysis. ProBioGen also provides process development services and manufacturing technologies for viral vaccines. Our additional new building houses 1000 L single-use bioreactor capacity to keep up with the ever-increasing demand from our clients. A second 1000 L single-use bioreactor is coming soon. With 30 years of experience in animal cell culture, combined with innovative scientific excellence and a strong intellectual property base, we cover the entire drug development value chain end-to-end. Watch & learn more: https://youtu.be/vtEgrEVfj70

Vibalogics is a viral vector CDMO that offers a unique understanding of virotherapy for high quality and resource-efficient delivery.